NCT05222620
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have at least one brain metastasis that has not been radiated that measures between 2.0-4.0 cm
Exclusions: Patients with previous whole brain radiation; Patients with any brain metastasis located in the brainstem measuring greater than or equal to 2.0 cm; Patients with an intact brain metastasis measuring greater than 4.0 cm; Patients with leptomeningeal metastasis (LMD)
https://ClinicalTrials.gov/show/NCT05222620